KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Short term Debt: 2009-2025

Historic Short term Debt for Teva Pharmaceutical Industries (TEVA) over the last 13 years, with Sep 2025 value amounting to $24.0 million.

  • Teva Pharmaceutical Industries' Short term Debt fell 99.07% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year decrease of 99.07%. This contributed to the annual value of $1.8 billion for FY2024, which is 6.52% up from last year.
  • Teva Pharmaceutical Industries' Short term Debt amounted to $24.0 million in Q3 2025, which was down 94.83% from $464.0 million recorded in Q2 2025.
  • Teva Pharmaceutical Industries' 5-year Short term Debt high stood at $3.5 billion for Q2 2021, and its period low was $24.0 million during Q3 2025.
  • In the last 3 years, Teva Pharmaceutical Industries' Short term Debt had a median value of $1.7 billion in 2023 and averaged $1.5 billion.
  • In the last 5 years, Teva Pharmaceutical Industries' Short term Debt spiked by 199.12% in 2024 and then tumbled by 99.07% in 2025.
  • Over the past 5 years, Teva Pharmaceutical Industries' Short term Debt (Quarterly) stood at $1.4 billion in 2021, then skyrocketed by 47.90% to $2.1 billion in 2022, then declined by 20.72% to $1.7 billion in 2023, then climbed by 6.52% to $1.8 billion in 2024, then plummeted by 99.07% to $24.0 million in 2025.
  • Its last three reported values are $24.0 million in Q3 2025, $464.0 million for Q2 2025, and $421.0 million during Q1 2025.